Atomo Diagnostics Ltd.ASX: AT1

Atomo and Access Bio renegotiate supply agreements

· Issued by Atomo Diagnostics Ltd.

Filed with ASX · · 2 pages · English

reflect the evolving structural changes in the COVID-19 diagnostics market. Under the new agreement, which has immediate effect and expires on 31 December 2022, Atomo will receive from Access Bio a one-off fee considered by Atomo to be material and replacing any payments due to Atomo under the existing agreements. The new agreement also provides Atomo the right, but not the obligation, to purchase

Atomo Diagnostics Ltd. on 6ix

Story so far

Earlier from Atomo Diagnostics

Later from Atomo Diagnostics

All Atomo Diagnostics news releases